The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment DOI Creative Commons

Haohui Sun,

Yue Hao, Hao Liu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 11, 2025

Glucagon-like peptide-1 (GLP-1) receptor is widely distributed in the digestive system, cardiovascular adipose tissue and central nervous system. Numerous GLP-1 receptor-targeting drugs have been investigated clinical studies for various indications, including type 2 diabetes obesity (accounts 70% of total studies), non-alcoholic steatohepatitis, Alzheimer's disease, Parkinson's disease. This review presented fundamental information regarding two categories agonists (GLP-1RAs): peptide-based small molecule compounds, elaborated their potential neuroprotective effects by inhibiting neuroinflammation, reducing neuronal apoptosis, ultimately improving cognitive function neurodegenerative diseases. As a new hypoglycemic drug, GLP-1RA has unique role concurrent risk stroke T2D patients. Given infiltration peripheral immune cells into brain tissue, particularly areas surrounding infarct lesion, we further regulatory mechanisms. could not only facilitate M2 polarization microglia through both direct indirect pathways, but also modulate quantity T cell subtypes, CD4, CD8, cells, resulting inhibition inflammatory responses promotion regeneration interleukin-10 secretion. Therefore, believe that "Tregs-microglia-neuron/neural precursor cells" axis instrumental mediating suppression neuroprotection context ischemic stroke. benefits rapid diffusion, favorable blood-brain barrier permeability versatile administration routes, these compounds will be one important candidates GLP-1RA. We look forward to evidence intervention or complicated

Language: Английский

Beyond weight loss: exploring the neurological ramifications of altered gut microbiota post-bariatric surgery DOI Creative Commons

Rashed T. Almheiri,

Baraa Hajjar,

Saif M. I. Alkhaaldi

et al.

Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 24, 2025

Language: Английский

Citations

0
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies DOI Creative Commons
S. Thompson, Ashwin Roy, Tarekegn Geberhiwot

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 624 - 624

Published: March 4, 2025

Fabry disease (FD) is an X-linked lysosomal storage disorder characterized by deficiency of α-galactosidase A (α-GalA), leading to the accumulation glycosphingolipids and multi-organ dysfunction, particularly affecting cardiovascular renal systems. Disease-modifying treatments such as enzyme replacement therapy (ERT) oral chaperone (OCT) have limited efficacy, in advanced disease, prompting a need for innovative therapeutic approaches targeting underlying molecular mechanisms beyond glycosphingolipid alone. Recent insights into pathophysiology FD highlights chronic inflammation mitochondrial, lysosomal, endothelial dysfunction key mediators progression. Adjunctive therapies sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, mineralocorticoid receptor antagonists (MRAs) demonstrate significant benefits conditions including heart failure kidney disease. These drugs also modulate pathways involved FD, autophagy, oxidative stress, pro-inflammatory cytokine signaling. While theoretical foundations support their utility, dedicated trials are necessary confirm efficacy FD-specific population. This narrative review importance expanding strategies advocating multi-faceted approach involving evidence-based adjunctive improve outcomes. Tailored research focusing on diverse phenotypes, females non-classical variants will be critical advancing care improving outcomes this complex disorder.

Language: Английский

Citations

0
New Markers for the Assessment of Microvascular Complications in Patients with Metabolic Syndrome DOI Creative Commons

Diana Nikolova,

Zdravko Kamenov

Metabolites, Journal Year: 2025, Volume and Issue: 15(3), P. 184 - 184

Published: March 10, 2025

Background: Metabolic syndrome is a complex disorder characterized by the coexistence of multiple risk factors, including dysglycemia, hypertension, dyslipidemia, and visceral obesity. Both metabolic diabetes mellitus are closely associated with onset microvascular complications such as retinopathy, polyneuropathy, nephropathy. Methods: This narrative review analyzed 137 studies published up to 2025, retrieved from PubMed Crossref databases. The objective was identify evaluate potential biomarkers that could facilitate early detection in patients syndrome. Results: Several demonstrated strong correlation individuals These findings suggest their role diagnosis assessment. Conclusions: identification reliable may enhance targeted interventions for Further research essential validate these markers establish clinical applicability routine medical practice.

Language: Английский

Citations

0
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities DOI Creative Commons
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon

et al.

Peptides, Journal Year: 2025, Volume and Issue: 187, P. 171380 - 171380

Published: March 11, 2025

Recent studies with peptide-based incretin herapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and dual tirzepatide that engages receptors for GLP-1 glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials 'real-world' confirmed marked glucose-lowering weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young elderly individuals without diabetes and/or overweight or obesity. also protections against development progression cardiovascular renal diseases are additive to benefits conferred by improved control blood glucose body weight. Emerging evidence suggests therapies could additionally ameliorate fatty liver disease, chronic inflammation, sleep apnea possibly degenerative bone disorders cognitive decline. New incretin-based peptide in a long-acting glucagon (LY3324954), GLP-1/glucagon agonists (survodutide, pemvidutide, mazdutide, G49), triple GLP-1/GIP/glucagon (retatrutide, efocipegtrutide), combination amylin analogue cagrilintide (CagriSema), unimolecular GLP-1/amylin (amycretin), GIP antibody agonism (MariTide). The creation multi-targeting synthetic peptides provides opportunities management type 2 obesity as well new therapeutic approaches an expanding list associated co-morbidities. aim review is acquaint reader developments field from 2023 present (February 2025).

Language: Английский

Citations

0
The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment DOI Creative Commons

Haohui Sun,

Yue Hao, Hao Liu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 11, 2025

Glucagon-like peptide-1 (GLP-1) receptor is widely distributed in the digestive system, cardiovascular adipose tissue and central nervous system. Numerous GLP-1 receptor-targeting drugs have been investigated clinical studies for various indications, including type 2 diabetes obesity (accounts 70% of total studies), non-alcoholic steatohepatitis, Alzheimer's disease, Parkinson's disease. This review presented fundamental information regarding two categories agonists (GLP-1RAs): peptide-based small molecule compounds, elaborated their potential neuroprotective effects by inhibiting neuroinflammation, reducing neuronal apoptosis, ultimately improving cognitive function neurodegenerative diseases. As a new hypoglycemic drug, GLP-1RA has unique role concurrent risk stroke T2D patients. Given infiltration peripheral immune cells into brain tissue, particularly areas surrounding infarct lesion, we further regulatory mechanisms. could not only facilitate M2 polarization microglia through both direct indirect pathways, but also modulate quantity T cell subtypes, CD4, CD8, cells, resulting inhibition inflammatory responses promotion regeneration interleukin-10 secretion. Therefore, believe that "Tregs-microglia-neuron/neural precursor cells" axis instrumental mediating suppression neuroprotection context ischemic stroke. benefits rapid diffusion, favorable blood-brain barrier permeability versatile administration routes, these compounds will be one important candidates GLP-1RA. We look forward to evidence intervention or complicated

Language: Английский

Citations

0